Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.47 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6909466 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DPDE7A | |
| SCHEMBL5358605 | 0.92 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DPDE7A | |
| SCHEMBL14575983 | 0.92 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DPDE7A | |
| SCHEMBL5358600 | 0.92 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DPDE7A | |
| SCHEMBL5351643 | 0.92 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DPDE7A | |
| SCHEMBL5351649 | 0.92 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DPDE7A | |
| SCHEMBL14576476 | 0.89 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DPDE7A | |
| SCHEMBL14576959 | 0.89 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DPDE7A | |
| SCHEMBL14577241 | 0.88 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DPDE7A | |
| SCHEMBL14576596 | 0.88 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020169196-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2002-11-14 | — | — | US | claimed |
| US-6376489-B1 | PHENYL OR BENZYLPYRROLIDINE DERIVATIVES | ICOS CORPORATION | 2002-04-23 | — | — | US | claimed |
| US-6680336-B2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASES INHIBITORS; ANTIINFLAMMATORY AGENTS; 2,3-DIOXY-4-PYRROLE SUBSTITUTED PHENYL DERIVATIVES | ICOS CORPORATION | 2004-01-20 | — | — | US | disclosed |
| US-20020169196-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2002-11-14 | — | — | US | disclosed |
| US-6376489-B1 | PHENYL OR BENZYLPYRROLIDINE DERIVATIVES | ICOS CORPORATION | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169196-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.